{"title":"Farmaci per Infezioni e Lesioni della Pelle","description":"\u003cp\u003eFarmaci per la pelle infetta o lesa: antibiotici e chemioterapici topici, sulfadiazina argentica, creme riparatrici e cicatrizzanti per ferite e piaghe, collodi e cerotti cheratolitici per verruche e calli, trattamenti per acne e rosacea. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"duofilm-16-7-15-collodio-15ml","title":"Duofilm 16.7% + 15% collodion 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDUOFILM is indicated for the topical treatment of warts, corns and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of collodion contain: Active ingredients: salicylic acid 16.7 g; lactic acid 15 g. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: ethyl alcohol. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe only excipient of DUOFILM is the elastic collodion BP, consisting of: rosin, castor oil and collodion, in turn consisting of pyroxylin, \u003cb\u003eethyl alcohol\u003c\/b\u003e and ether.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine is contraindicated in patients with a previous hypersensitivity reaction to the active substances or to any of the excipients listed in paragraph 6.1. Do not use on open wounds, irritated or red skin, or any infected area. DUOFILM should not be applied to the face, anogenital area and large areas. The product should not be applied to moles, birthmarks, seborrheic warts, warts, facial or mucous membrane warts, or hairy warts surrounded by red or unusually colored edges.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eFor topical use only\u003c\/u\u003e \u003cu\u003eAdults, including the elderly \u003c\/u\u003e DUOFILM must be applied using the appropriate brush only on the affected part, avoiding the liquid coming into contact with healthy skin. DUOFILM must be applied to the wart, callus or corn once a day, preferably in the evening before going to bed, following the following instructions for use: 1. Immerse the part to be treated in hot water for about 5 minutes and dry carefully with a clean towel. 2. Pass the affected surface with a nail file, an abrasive stone, a cardboard file or a rough cloth, taking care not to cause bleeding. 3. Apply with the appropriate DUOFILM brush on the wart, callus or corn, taking care not to overflow onto the surrounding healthy skin. 4. Allow the solution to dry completely: in the case of localized forms on the feet or if the wart, callus or callus involve large areas, the area must be covered with a plaster to facilitate the absorption of the active ingredients. It is recommended to continue treatment until one of the following conditions occurs: - the corns and calluses have been treated for 2 weeks - the warts have been treated for 12 weeks - or until the wart, callus or corn is completely removed and the normal wrinkling of the skin has been restored. For warts, a clinically visible improvement should be observed in 1-2 weeks but the maximum effect is expected after 4-8 weeks. Advise the patient to consult their doctor or pharmacist if the wart persists beyond 12 weeks of treatment. Consider alternative treatment if warts cover a large area of ​​the body (more than 5 cm²) (see Special warnings and precautions for use). Advise the patient to consult their doctor or pharmacist if skin irritation develops. Due to the flammable nature of the medicine, patients should avoid smoking or going near open flames during application and immediately after use. \u003ci\u003ePediatric population\u003c\/i\u003e Do not administer under two years of age. In children between 2 and 12 years of age, the product must be administered only if clearly necessary and under direct medical supervision. Use in children must take place under the supervision of an adult. Elderly No dose adjustment is required since significant systemic exposure is not expected. Hepatic impairment No dose adjustment is required as significant systemic exposure is not expected. Renal insufficiency No dose adjustment is required since significant systemic exposure is not expected. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDue to its high flammability, it is recommended to store the product at temperatures not exceeding 25°C, away from flames and heat sources. Close the bottle tightly after use. A notable increase in density of the product indicates that the bottle has not been closed properly and that the solvent contained in it has partially evaporated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Apply DUOFILM only on warts without overflowing onto the surrounding healthy skin. The medicine may cause eye irritation. Avoid contact with eyes and other mucous membranes. If the product accidentally comes into contact with mucous membranes or eyes, rinse immediately and abundantly with water, remove the collodion film that forms and continue rinsing with water for at least a quarter of an hour. Avoid application on healthy skin (see Side effects). The medicine may cause skin irritation. If unexpected skin irritation develops, treatment should be discontinued. Consider alternative treatment if warts cover a large area of ​​the body (more than 5 cm²) due to the potential toxicity of salicylates. The medicine is not recommended in diabetic patients or patients with circulatory problems or peripheral neuropathy, unless under the supervision of a doctor. Taking oral salicylates during or immediately after a viral illness has been associated with Reye's syndrome and consequently there is a theoretical risk also with topical salicylates. Therefore, the product should not be used in children or adolescents during or immediately after chickenpox, influenza or other viral infections. Salicylates have been reported to be excreted in breast milk (see Fertility, pregnancy and lactation). Patients should be advised not to inhale vapours. Accidental ingestion of keratolytics containing salicylic acid and lactic acid at high concentrations can have serious, sometimes fatal, consequences. The product must not be used to prevent the formation of warts. Do not ingest. Keep out of the sight and reach of children. This medicinal product contains 2228 mg of alcohol (ethanol) in each unit volume which is equivalent to 158 mg\/g. May cause burning sensation on damaged skin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid and lactic acid topical solution may increase the absorption of other topical medications. Therefore the concomitant use of salicylic acid and lactic acid solution and other topical medicines on the treated area should be avoided. Since the systemic absorption of topical solutions of salicylic acid and lactic acid is low, interaction with systemically administered medicinal products is not expected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following convention is used to classify the frequency of an adverse reaction and is based on the CIOMS guidelines: • very common (\u003e 1\/10), • common (\u003e 1\/100 to \u003c 1\/10), • uncommon (\u003e1\/1,000 to \u003c 1\/100), • rare (\u003e 1\/10,000 to \u003c 1\/1,000) and • very rare (\u003c 1\/10,000), • not known (frequency cannot be estimated from the available data). Data from clinical studies:\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin rash.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin hypertrophy.\u003c\/p\u003e\n\u003cp\u003ePost marketing data\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare: Application site hypersensitivity reaction including inflammation.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eRare: Application site pain and irritation, skin discolouration at the application site\/skin discolouration. Exposure of healthy skin may lead to skin exfoliation and blistering (see Special warnings and precautions for use). Allergic dermatitis.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSigns and symptoms \u003c\/u\u003e In case of accidental oral ingestion, symptoms of salicylate toxicity may occur. The risk of developing symptoms of salicylate poisoning or salicylism increases if salicylic acid and lactic acid topical solution is used in excess or for prolonged periods of time. It is therefore very important to respect the recommended duration and frequency of treatment. \u003cu\u003eTreatment \u003c\/u\u003e Overdose should be treated as clinically indicated or as recommended by the poison control center, where available. There is no specific treatment for accidental oral ingestion of lactic acid and salicylic acid solutions. In case of accidental ingestion, the patient should be treated according to local guidelines under appropriate observation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e The safety of use of the salicylic acid and lactic acid solution during pregnancy has not been established. Studies in animals administered oral salicylic acid have demonstrated embryotoxicity at high doses (see Preclinical safety data). The medicine is not recommended during pregnancy. \u003cu\u003eBreastfeeding \u003c\/u\u003e Salicylates are excreted in breast milk. The medicine is not recommended during breastfeeding. If used or administered during breastfeeding, avoid contact with the breast area to prevent accidental ingestion by the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo effects are expected based on the safety profile of the product.\u003c\/p\u003e","brand":"Eg","offers":[{"title":"Default Title","offer_id":51131289010503,"sku":"034522019","price":15.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eg-spa-duofilm-16-7-15-collodio-15ml-farmacia-dottor-tili-1213792222.jpg?v=1767134130"},{"product_id":"streptosil-con-neomicina-99-5-0-5-polvere-cutanea-10g","title":"Streptosil with neomycin 99.5% + 0.5% skin powder 10g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSuperficial skin infections (folliculitis, furunculosis, small burns and infected wounds).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e10 g of powder contains: sulfathiazole 9.95 g and neomycin sulphate 0.05 g. 20 g of ointment contains: sulfathiazole 0.4 g and neomycin sulfate 0.1 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eskin powder: none. ointment: Vaseline oil, white Vaseline, white wax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is contraindicated in patients with: - Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Infections of the ear canal in case of perforation of the tympanic membrane.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSkin dust\u003c\/b\u003e Lift the colored cap, rhythmically and thoroughly press the two faces of the bottle, holding it horizontally or slightly obliquely; lightly sprinkle the affected region with the powder and cover with sterile gauze; renew the application twice a day. It is recommended to apply a light sprinkling, using the minimum amount of powder necessary to avoid the formation of crusts and allow rapid dissolution and diffusion of the components. Do not exceed the recommended doses. \u003cb\u003eOintment\u003c\/b\u003e Apply a thin layer of ointment 2-3 times a day. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is not for ophthalmic use; it is indicated for external use only. The application of STREPTOSIL with NEOMICIN on extensively and deeply damaged skin, such as in skin infections secondary to extensive burns and trophic ulcers, could favor the systemic absorption of its active ingredients, exposing patients to serious secondary effects, such as nephrotoxicity and ototoxicity. The medicine must not be used in ear canal infections in case of perforation of the eardrum since in these cases the topical use of neomycin can cause deafness (see section 4.3). As with other aminoglycosides, the simultaneous and\/or sequential systemic or topical administration of other nephrotoxic drugs should be avoided. \u003ci\u003eDuration of treatment\u003c\/i\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. As with other antibiotics, prolonged use of neomycin can lead to the development of resistant microorganisms, including fungi. If this occurs it is necessary to discontinue treatment and institute appropriate therapy. After a short period of treatment without appreciable results, or in case of worsening of the patient's condition, it is necessary to consider suspending treatment. \u003ci\u003e Pediatric population\u003c\/i\u003e In early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. The application of neomycin on large areas of the skin and for prolonged periods can lead to systemic absorption; this eventuality occurs more easily when occlusive bandage is used, in particular in newborns, since the diaper can act as an occlusive bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical neomycin has demonstrated cross-sensitivity with other aminoglycosides; co-administration of another aminoglycoside, especially systemically, is not recommended due to potential ototoxic and nephrotoxic effects. Topical application of sulfathiazole may result in sensitization and preclude subsequent systemic use of sulfonamides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of STREPTOSIL with NEOMICIN, the side effects indicated below may occur. The frequency of these side effects is not known. \u003cu\u003eInfections and infestations\u003c\/u\u003e Bacterial and fungal superinfections. \u003cu\u003eImmune system disorders\u003c\/u\u003e Hypersensitivity reactions \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e Itching. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e Swelling, redness. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the event of prolonged applications on large surfaces or lesions, systemic absorption of the medicine may occur with passage of sulfathiazole and\/or neomycin into circulation. If overdose is suspected, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy \u003c\/i\u003e The safety of topical use of sulfonamides or neomycin during pregnancy has not been established. In pregnant women, the product should be administered in cases of actual need, under the direct supervision of a doctor. \u003ci\u003eBreastfeeding\u003c\/i\u003e There are no adequate studies available to evaluate the effects in women during breastfeeding and therefore to determine the risk in infants. The product should be used in breastfeeding women only if strictly necessary, under the direct supervision of a doctor. \u003ci\u003eFertility\u003c\/i\u003e No studies have been conducted to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN has no or negligible influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Cheplapharm","offers":[{"title":"Default Title","offer_id":51131295760711,"sku":"023589031","price":10.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/cheplapharm-arzneimittel-gmbh-streptosil-con-neomicina-99-5-0-5-polvere-cutanea-10g-farmacia-dottor-tili-1213792203.jpg?v=1767134508"},{"product_id":"trofodermin-5-5-30-ml-spray-cutaneo-soluzione","title":"Trofodermin 5% + 5% 30 ml cutaneous spray solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbrasions and erosions; ulcerative skin lesions (variceal ulcers, bedsores, traumatic ulcers); nipple fissures, anal fissures; burns; infected wounds; healing delays; radiodermatitis; dystrophic skin conditions (dryness, cracking, flaking).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e 100 g contain: Clostebol acetate 500 mg; neomycin sulphate 500 mg. Excipients with known effects: lanolin, nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate). \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e One 30 ml pressurized container contains: Clostebol acetate 0.150 g; neomycin sulphate 0.150 g. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e Polyethylene glycol stearate; stearic acid; liquid paraffin; lanolin; dimethicone; nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate); floranol; purified water. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e Magnesium stearate; liquid paraffin; isobutane at 3.2 bar.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e: 1–2 applications per day. Spread a thin layer of cream on the injured part and possibly cover the injured part with sterile gauze. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e:1–2 applications per day; If necessary, cover the injured part with sterile gauze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e For storage conditions after first opening, see paragraph 6.3. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e Protect from sunlight and do not expose to temperatures above 50° C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eContinuous use of Trofodermin should be avoided. Due to the potential risk of ototoxicity and nephrotoxicity of neomycin, prolonged use of the product on large damaged surfaces that could allow the absorption of neomycin is not recommended. \u003cu\u003ePediatric population\u003c\/u\u003e Continuous use of Trofodermin should be avoided; especially in early childhood. \u003ci\u003eTrofodermin 5 mg\/ml + 5 mg\/ml cutaneous spray, suspension\u003c\/i\u003e As regards the spray, it is recommended to shake before use, not to spray on a flame or incandescent body, not to turn upside down during dispensing, not to inhale or spray into the eyes. \u003ci\u003eTrofodermin 500 mg\/100 g + 500 mg\/100 g cream\u003c\/i\u003e contains: – lanolin: can cause local skin reactions (e.g. contact dermatitis) – nipasept (methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate and propyl para-hydroxybenzoate): can cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe combined use of Trofodermin with topical preparations containing other aminoglycoside antibiotics may increase the risk of sensitization or enhance any secondary effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. Furthermore, prolonged application for several weeks on large areas of damaged tissue could give rise to the appearance of systemic effects, such as hypertrichosis due to massive absorption of clostebol. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of overdose can only be contemplated in the case of prolonged applications and on large areas of damaged skin, which could induce secondary effects of the type indicated above. In this case the treatment will need to be suspended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDuring pregnancy and breastfeeding, the drug should only be administered if clearly needed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTrofodermin is not known to interfere with the ability to drive or use machinery.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730202591559,"sku":"020942049","price":12.54,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-trofodermin-5-5-30-ml-spray-cutaneo-soluzione-farmacia-dottor-tili-1213791406.jpg?v=1767138167"},{"product_id":"streptosil-neomicina-2-0-5-20-g-unguento","title":"Streptosyl neomycin 2% + 0.5% 20 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSuperficial skin infections (folliculitis, furunculosis, small burns and infected wounds).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e10 g of powder contains: sulfathiazole 9.95 g and neomycin sulfate 0.05 g. 20 g of ointment contains: sulfathiazole 0.4 g and neomycin sulfate 0.1 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eskin powder: none. ointment: Vaseline oil, white Vaseline, white wax.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is contraindicated in patients with: - Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. - Infections of the ear canal in case of perforation of the tympanic membrane.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSkin dust\u003c\/b\u003e Lift the colored cap, rhythmically and thoroughly press the two faces of the bottle, holding it horizontally or slightly obliquely; lightly sprinkle the affected region with the powder and cover with sterile gauze; renew the application twice a day. It is recommended to apply a light sprinkling, using the minimum amount of powder necessary to avoid the formation of crusts and allow rapid dissolution and diffusion of the components. Do not exceed the recommended doses. \u003cb\u003eOintment\u003c\/b\u003e Apply a thin layer of ointment 2-3 times a day. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN is not for ophthalmic use; it is indicated for external use only. The application of STREPTOSIL with NEOMICIN on extensively and deeply damaged skin, such as in skin infections secondary to extensive burns and trophic ulcers, could favor the systemic absorption of its active ingredients, exposing patients to serious secondary effects, such as nephrotoxicity and ototoxicity. The medicine must not be used in ear canal infections in case of perforation of the eardrum since in these cases the topical use of neomycin can cause deafness (see section 4.3). As with other aminoglycosides, the simultaneous and\/or sequential systemic or topical administration of other nephrotoxic drugs should be avoided. \u003ci\u003eDuration of treatment\u003c\/i\u003e The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. As with other antibiotics, prolonged use of neomycin can lead to the development of resistant microorganisms, including fungi. If this occurs it is necessary to discontinue treatment and institute appropriate therapy. After a short period of treatment without appreciable results, or in case of worsening of the patient's condition, it is necessary to consider suspending treatment. \u003ci\u003e Pediatric population\u003c\/i\u003e In early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. The application of neomycin on large areas of the skin and for prolonged periods can lead to systemic absorption; this eventuality occurs more easily when occlusive bandage is used, in particular in newborns, since the diaper can act as an occlusive bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical neomycin has demonstrated cross-sensitivity with other aminoglycosides; co-administration of another aminoglycoside, especially systemically, is not recommended due to potential ototoxic and nephrotoxic effects. Topical application of sulfathiazole may result in sensitization and preclude subsequent systemic use of sulfonamides.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of STREPTOSIL with NEOMICIN, the side effects indicated below may occur. The frequency of these side effects is not known. \u003cu\u003eInfections and infestations\u003c\/u\u003e Bacterial and fungal superinfections. \u003cu\u003eImmune system disorders\u003c\/u\u003e Hypersensitivity reactions \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e Itching. \u003cu\u003eSystemic pathologies and conditions relating to the administration site\u003c\/u\u003e Swelling, redness. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the event of prolonged applications on large surfaces or lesions, systemic absorption of the medicine may occur with passage of sulfathiazole and\/or neomycin into circulation. If overdose is suspected, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy \u003c\/i\u003e The safety of topical use of sulfonamides or neomycin during pregnancy has not been established. In pregnant women, the product should be administered in cases of actual need, under the direct supervision of a doctor. \u003ci\u003eBreastfeeding\u003c\/i\u003e There are no adequate studies available to evaluate the effects in women during breastfeeding and therefore to determine the risk in infants. The product should be used in breastfeeding women only if strictly necessary, under the direct supervision of a doctor. \u003ci\u003eFertility\u003c\/i\u003e No studies have been conducted to evaluate the effects on fertility in humans.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSTREPTOSIL with NEOMICIN has no or negligible influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Cheplapharm","offers":[{"title":"Default Title","offer_id":51730202853703,"sku":"023589043","price":11.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/cheplapharm-arzneimittel-gmbh-streptosil-neomicina-2-0-5-20-g-unguento-farmacia-dottor-tili-1213791441.jpg?v=1767138250"},{"product_id":"metronidazolo-same-1-30-g-gel","title":"Metronidazole Same 1% 30g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMETRONIDAZOLE SAME is indicated for topical application in the treatment of inflammatory papules, pustules and erythema of rosacea.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains: Active ingredient: METRONIDAZOLE 1.0 g. \u003cu\u003eExcipient with known effects\u003c\/u\u003e: methyl parahydroxybenzoate (E218) (0.18 g per 100 g). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOctyldodecanol, caprylocaproyl macrogol-8 glycerides, carbomer, methyl parahydroxybenzoate (E218), sodium hydroxide, sodium edetate, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Contraindicated during pregnancy and breastfeeding (see p.4.6).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply 1-2 times a day, according to medical indications and after cleansing the affected areas, a thin layer of METRONIDAZOLE SAME. Significant therapeutic results should be observed within three weeks of starting treatment. Clinical studies have demonstrated progressive improvement for up to nine weeks of therapy. After applying METRONIDAZOLE SAME it is possible to use cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not freeze or refrigerate.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, due to the minimal absorption of Metronidazole applied locally and, consequently, the negligible plasma concentrations, the side effects reported following oral administration of the drug were not recorded following topical application. Avoid contact with eyes and mucous membranes; Metronidazole applied to the face has been reported to cause tearing. In case of contact with eyes, the gel must be carefully removed with water. The patient should be informed that if irritation occurs, he or she should use Metronidazole Same less frequently or temporarily suspend therapy and inform the doctor. Avoid exposure to ultraviolet light (sun, UV lamps, tanning equipment) during therapy with Metronidazole Same. Since the drug is a nitroimidazole derivative it must be used with caution in patients presenting with blood dyscrasias or with anamnestic data relating to them. The product must be used according to the instructions provided by the treating doctor. Do not exceed the recommended doses. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. There are no adequate clinical data on the efficacy and safety of Metronidazole Same in children, therefore Metronidazole Same should not be used in children. Do not ingest. Keep out of reach of children. This medicine contains methyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn consideration of the low blood levels resulting from the topical application of Metronidazole, interactions with other drugs are unlikely. However, it must be remembered that disulfiram-like reactions have been reported in a small number of patients taking metronidazole and alcohol at the same time and in the case of treatment of patients undergoing anticoagulant therapy at the same time, it must be kept in mind that Metronidazole, following oral administration, determines an enhancement of the anticoagulant effects of coumarins and warfarin which manifests itself by inducing a prolongation of the prothrombin time. The effect of topical metronidazole on prothrombin time is not known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFollowing the use of topical Metronidazole, the following side effects have been reported: Skin and subcutaneous tissue disorders: contact dermatitis, dry skin, erythema, itching, rash, skin discomfort (burning and stinging sensation), skin irritation, transient redness and worsening of rosacea. Eye disorders: tearing. None of these side effects occurred in more than 2% of treated patients. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported following topical application of Metronidazole.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of use of metronidazole during pregnancy has not been sufficiently demonstrated. Conflicting reports are available, especially regarding the early stage of pregnancy. Some studies have given indications of an increased rate of malformations. The risk of possible sequelae, including a carcinogenic risk, has not yet been clarified. Metronidazole Same is contraindicated during the first trimester of pregnancy. During the middle trimester and during the last trimester of pregnancy, Metronidazole Same should be administered only in case of failure of other treatments. Following oral administration, Metronidazole is secreted into breast milk in concentrations similar to those found in plasma. Following topical application the drug reaches plasma levels significantly lower than those obtained after oral administration, therefore the treating doctor will have to decide whether to interrupt breastfeeding or treatment with the drug by appropriately evaluating the importance of the therapeutic treatment for the mother.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMetronidazole Same does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Savoma","offers":[{"title":"Default Title","offer_id":51730203312455,"sku":"028523013","price":15.68,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/savoma-metronidazolo-same-1-30-g-gel-farmacia-dottor-tili-1258975901.jpg?v=1789560492"},{"product_id":"rozex-0-75-50-g-crema","title":"Rozex 0.75% 50g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRozex 0.75% cream is indicated in the topical treatment of rosacea in its erythematous and papulopustular manifestations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of cream contains: \u003cu\u003eActive Ingredient:\u003c\/u\u003e Metronidazole 0.75 g Excipients with known effects: Cetylstearyl alcohol 81-106 mg\/g One gram of cream contains 22 mg of benzyl alcohol (E1519). For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEmulsified waxes (cetylstearyl alcohol and polysorbate 60), 70% non-crystallized sorbitol, glycerol, isopropyl palmitate, benzyl alcohol (E1519), lactic acid and\/or sodium hydroxide to adjust the pH, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply twice a day, morning and evening, a thin layer of Rozex 0.75% cream to the affected area, properly cleansed with a delicate cleanser, rubbing lightly. After applying Rozex 0.75% cream you can use non-comedogenic and non-astringent cosmetics. Treatment in elderly patients does not require dosage adjustment. During clinical use, improvements occurred within the first three weeks of treatment and continued progressively through the 12th week. The average duration of treatment usually varies from three to four months. The recommended duration of treatment should not be exceeded. However, in the event that a clear benefit has been demonstrated, the treatment can be extended according to medical opinion for a further period which varies from three to four months based on the severity of the condition. In clinical trials, topical metronidazole therapy for the treatment of rosacea was continued for up to two years. In the absence of evident clinical improvement, therapy should be discontinued. \u003ci\u003ePediatric population\u003c\/i\u003e In the absence of data on safety and efficacy, the use of Rozex 0.75% cream is not recommended in children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid contact with eyes and mucous membranes. During therapy with metronidazole, avoid exposure to UV rays (exposure to sun rays, solariums and sun lamps). Metronidazole converts into an inactive metabolite as a result of UV exposure, therefore its effectiveness decreases significantly. No side effects of phototoxicity have been reported in clinical studies in relation to metronidazole. If a reaction due to local irritation should occur, it is advisable to reduce the number of daily applications of the drug or to suspend administration according to the doctor's opinion. Metronidazole is a nitroimidazole compound and should therefore be used with caution in patients with blood dyscrasia. Avoid unnecessary and prolonged use of this medicine. Metronidazole has been shown to be carcinogenic in some animal species. There are no data demonstrating its carcinogenic effect in humans. \u003cb\u003eImportant information about some excipients.\u003c\/b\u003e \u003cb\u003eRozex 0.75% cream contains: cetylstearyl alcohol which may cause localized skin reactions (e.g. contact dermatitis). This medicinal product also contains 22 mg of benzyl alcohol (E1519) per gram, equivalent to 2.2% w\/w, which may cause allergic reactions and mild local irritation.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eConsidering the poor systemic absorption of Rozex 0.75% cream applied topically, negative interactions with other drugs are quantitatively irrelevant. Metronidazole administered orally can lead to an enhancement of the effects of anticoagulant drugs. An increase in prothrombin time has been observed after concomitant administration of oral metronidazole and an oral coumarin-type anticoagulant (Warfarin). The effect of topical metronidazole on prothrombin time is unknown. Furthermore, in a small number of patients taking oral metronidazole and alcohol at the same time, a reaction similar to that which occurs with Disulfiram occurred.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOnly mild local reactions occurred during topical use of Rozex 0.75% cream. The following spontaneous adverse reactions have been reported and these are ranked by frequency within system organ classes, according to the following convention: very common (≥ 1\/10) common (≥ 1\/100, \u003c 1\/10) uncommon (≥ 1\/1,000, \u003c 1\/100) rare (≥ 1\/10,000, \u003c 1\/1,000) very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data) \u003cu\u003ePathology of the skin and subcutaneous tissue:\u003c\/u\u003e Common: dry skin, erythema, pruritus, skin discomfort (burning, skin pain, stinging), skin irritation, worsening of rosacea. Not known: contact dermatitis, skin exfoliation, facial swelling. \u003cu\u003eNervous system disorders:\u003c\/u\u003e Uncommon: hypoesthesia, paraesthesia, dysgeusia (metallic taste).\u003cu\u003eGastrointestinal disorders:\u003c\/u\u003e Uncommon: nausea. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with the topical use of Rozex 0.75% cream in humans. Acute oral toxicity studies with topical metronidazole gel formulation at 0.75% w\/w in rats did not show toxic action at doses up to 5 g maximum administered dose of finished product per kilo body weight. This dose is equivalent to the oral intake of 12 tubes of 30 g of Rozex cream for an adult weighing 72 kg and 2 tubes of 30 g for a child weighing 12 kg.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e In animal studies, metronidazole administered orally crosses the placenta, enters the fetal circulation and was neither teratogenic nor embryotoxic at therapeutic doses; since there are no clinical data on the effects of topical preparations administered during pregnancy, during this period the drug must be used only in cases of actual need under the direct supervision of a doctor. \u003cu\u003eBreastfeeding\u003c\/u\u003e After oral administration, concentrations of metronidazole in breast milk are similar to those found in plasma. Regarding the topical administration of Rozex 0.75% cream during breastfeeding, it is advisable to evaluate the possibility of suspending breastfeeding or the use of the drug depending on actual needs, even if the serum levels of the drug are significantly reduced compared to the levels achieved following oral administration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRozex 0.75% cream does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730203869511,"sku":"028809085","price":37.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-rozex-0-75-50-g-crema-farmacia-dottor-tili-1213791418.jpg?v=1767138750"},{"product_id":"fitostimoline-15-32-g-crema-garze-impregnate","title":"Fitostimoline 15% 32 g cream + impregnated gauze","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e: treatment of ulcers and bedsores\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePHYTOSTIMOLINES 15% Cream 100 g of cream contain the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. Excipients: cetyl alcohol; stearyl alcohol. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e Each gauze is impregnated to saturation with 4 g of cream containing, in 100 g, the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 1500; macrogol 3000; macrogol 4000; liquid paraffin; \u003cb\u003ecetyl alcohol; stearyl alcohol\u003c\/b\u003e; glycerine; purified water. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 600; macrogol 1500; macrogol 4000; glycerine; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e: The treatment involves at least two applications of cream per day. These applications, depending on the entity, extension and location of the manifestations, can be reduced to simple absorption massages, just as it may be necessary to cover the area according to the suggested application methods. • \u003ci\u003eApplication methods\u003c\/i\u003e: To open the tube for the first time, pierce the protective membrane of the tube using the perforator contained in the upper part of the closing cap. Spread as much cream as necessary on the area and cover with sterile gauze, possibly soaked in the same cream in order to maintain the softness and plasticity of the application. In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with simple sterile water, as the cream is completely water-dispersible and leaves no residue. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: The treatment ranges from one to two applications per day, taking care that the dressing always remains moist, soft and plastic. • \u003ci\u003eApplication methods\u003c\/i\u003e: Take the gauze with sterile forceps and apply it directly to the previously cleansed and disinfected area. Cover with sterile gauze and then with cotton wool (in the case of very secreting sores). In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with sterile water only, as the cream is completely water-dispersible and leaves no residue.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream: \u003c\/b\u003estore the product at a temperature not exceeding 30°C. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: store the product at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of all products for topical use can give rise to sensitization phenomena. If this occurs, treatment should be suspended and appropriate therapy instituted, if necessary. The same applies in the case of the development of insensitive germs. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePhytostimolines 15% Cream \u003c\/b\u003econtains cetyl and stearyl alcohol: they may cause localized skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions or incompatibilities.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo side clinical manifestations or unwanted secondary effects have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e they can be used without problems during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes \u003c\/b\u003ethey do not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Damor","offers":[{"title":"Default Title","offer_id":51730204098887,"sku":"009115027","price":17.1,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/farmaceutici-damor-spa-fitostimoline-15-32-g-crema-garze-impregnate-farmacia-dottor-tili-1213791412.jpg?v=1767138869"},{"product_id":"verunec-15-g-15-g-100-g-10-g-collodio","title":"Verunec 15 g + 15 g\/100 g 10 g collodion","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of vulgar, plantar and mosaic warts; calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of collodion contain: Active ingredients: SALICYLIC ACID 15 g, LACTIC ACID 15 g.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUrea, glycerin, elastic collodion USP (composed of camphor, castor oil, pyroxylin, ethyl ether, ethyl alcohol).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients. VERUNEC should not be used by diabetics or patients with impaired blood circulation. VERUNEC, like all products with a high salicylic acid content, should not be applied to the face and anogenital area.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a small quantity of product to the affected area twice a day (morning and evening), using the appropriate spatula. Allow to evaporate for a few minutes. VERUNEC leaves a protective film that does not require particular attention and is easily removable during subsequent applications. It is recommended, before using the product, to wet the application area for about 5 minutes in hot water and, from time to time (2-3 times a week), to rub it with a stone or abrasive file. The treatment must be continued until the callus is completely removed. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is flammable, keep the bottle tightly closed and away from flames or heat sources.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product must not be applied on: seborrheic warts, facial warts, warts, skin nevi. Avoid contact with eyes and mucous membranes. If the product is spilled into the eyes or on the mucous membranes, wash with water, remove the precipitated collodion and wash again with water for 15 minutes. Avoid application on normal skin surrounding the callus. The product is for external use only. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to institute suitable therapy. Do not ingest. In case of accidental ingestion of the product, consult a doctor immediately. The product must not be used to prevent the formation of warts. Keep out of reach of children. Do not use for prolonged treatments; after a short period of treatment without appreciable results, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substances.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocalized irritation may occur if the product is applied to the skin surrounding the hyperkeratotic formation. Normally irritation should be controlled by temporary suspension and application of the product only to the affected area when treatment is resumed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported. However, if an excessive dose of product is applied, wash immediately and carefully with water and consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe safety of use during pregnancy has not been established, therefore the product should only be used if clearly necessary and under the supervision of a doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known effects on the ability to drive and use machines.\u003c\/p\u003e","brand":"Savoma","offers":[{"title":"Default Title","offer_id":51730204754247,"sku":"034603011","price":11.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/savoma-verunec-15-g-15-g-100-g-10-g-collodio-farmacia-dottor-tili-1254215768.jpg?v=1786736413"},{"product_id":"fitostimoline-15-10-garze-impregnate-crema","title":"Fitostimoline 15% 10 gauzes impregnated with cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e: treatment of ulcers and bedsores\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePHYTOSTIMOLINES 15% Cream 100 g of cream contain the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. Excipients: cetyl alcohol; stearyl alcohol. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e Each gauze is impregnated to saturation with 4 g of cream containing, in 100 g, the following active ingredient: aqueous extract of Triticum vulgare (dry residue equal to 200 mg\/100 ml) 15 g. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 1500; macrogol 3000; macrogol 4000; liquid paraffin; \u003cb\u003ecetyl alcohol; stearyl alcohol\u003c\/b\u003e; glycerine; purified water. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e 2–phenoxyethanol; macrogol 400; macrogol 600; macrogol 1500; macrogol 4000; glycerine; purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream\u003c\/b\u003e: The treatment involves at least two applications of cream per day. These applications, depending on the entity, extension and location of the manifestations, can be reduced to simple absorption massages, just as it may be necessary to cover the area according to the suggested application methods. • \u003ci\u003eApplication methods\u003c\/i\u003e: To open the tube for the first time, pierce the protective membrane of the tube using the perforator contained in the upper part of the closing cap. Spread as much cream as necessary on the area and cover with sterile gauze, possibly soaked in the same cream in order to maintain the softness and plasticity of the application. In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with simple sterile water, as the cream is completely water-dispersible and leaves no residue. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: The treatment ranges from one to two applications per day, taking care that the dressing always remains moist, soft and plastic. • \u003ci\u003eApplication methods\u003c\/i\u003e: Take the gauze with sterile forceps and apply it directly to the previously cleansed and disinfected area. Cover with sterile gauze and then with cotton wool (in the case of very secreting sores). In subsequent dressings, unless there are specific contraindications, the area can be washed beforehand with sterile water only, as the cream is completely water-dispersible and leaves no residue.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePHYTOSTIMOLINES 15% Cream: \u003c\/b\u003estore the product at a temperature not exceeding 30°C. \u003cb\u003ePHYTOSTIMOLINES 15 % Impregnated gauzes\u003c\/b\u003e: store the product at a temperature not exceeding 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of all products for topical use can give rise to sensitization phenomena. If this occurs, treatment should be suspended and appropriate therapy instituted, if necessary. The same applies in the case of the development of insensitive germs. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003cb\u003ePhytostimolines 15% Cream \u003c\/b\u003econtains cetyl and stearyl alcohol: they may cause localized skin reactions (e.g. contact dermatitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions or incompatibilities.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo side clinical manifestations or unwanted secondary effects have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes\u003c\/b\u003e they can be used without problems during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFITOSTIMOLINES 15% Cream and FITOSTIMOLINES 15% Impregnated gauzes \u003c\/b\u003ethey do not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Damor","offers":[{"title":"Default Title","offer_id":51730204787015,"sku":"009115039","price":19.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/farmaceutici-damor-spa-fitostimoline-15-10-garze-impregnate-crema-farmacia-dottor-tili-1213791393.jpg?v=1767139210"},{"product_id":"benzac-gel-10-40-g-gel","title":"Benzac Gel 10% 40g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSkin disinfection. It also has antiseptic activity against P. acnes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: Benzoyl Peroxide - BENZAC 10% gel: 10 g. BENZAC 5% gel: 5 g.\u003c\/p\u003e\n\u003cp\u003eExcipient with known effects: Propylene glycol (E1520) For the complete list of excipients, see paragraph 6.1 Rinse-off formulation 100 g of gel contain:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: BENZAC 5% gel.\u003c\/p\u003e\n\u003cp\u003eBenzoyl Peroxide: 5 g.\u003c\/p\u003e\n\u003cp\u003eFor the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel and BENZAC 10% gel\u003c\/b\u003e Carbomer 940, Methacrylic copolymer, Glycerin, Disodium Edetate, Dioctyl sodium sulfosuccinate, Colloidal silica, Propylene glycol (E1520), Poloxamer 182, Demineralised water. \u003cb\u003eBENZAC 5% gel - rinse-off formulation\u003c\/b\u003e Acryl Copolymer, Carbomer 940, Sodium C14-C16 Olefin Sulphonate, Glycerol, Sodium Hydroxide, Demineralised Water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel\u003c\/b\u003e e \u003cb\u003eBENZAC 10% gel\u003c\/b\u003e: Apply Benzac locally on the skin, favoring its penetration with a light massage. Applications must be made once or twice a day, as needed, by spreading a small amount of Benzac with the fingertips on the affected parts, previously thoroughly cleaned with a mild detergent and dried carefully, massaging lightly until absorbed. People with sensitive skin should apply the gel once a day or once every two days before going to bed. \u003cb\u003eBENZAC 5% gel (rinse-off formulation)\u003c\/b\u003e: Apply the gel once or twice a day to the affected area. Moisten the application area. Place the required amount of BENZAC 5% gel on your fingertips and spread it on the various parts of the skin with a circular motion, as if washing. Skin contact time should be as short as possible (1 to 5 minutes) to minimize the risk of undesirable effects (see section 4.8). Rinse thoroughly with water and dry.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store Benzac above 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for external use only. The use, especially if prolonged, of products for skin use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Probably, at the first application you may feel a slight burning sensation and, within a few days, slight redness and peeling of the skin may occur. During the first weeks of treatment, a sudden increase in desquamation occurs in most patients. This is not dangerous and normally subsides within a day or two if treatment is temporarily stopped. Patients should be directed to use the drug less frequently, to temporarily discontinue or discontinue use, if severe irritation occurs. Benzoyl peroxide may cause swelling and blistering of the skin; if any of these symptoms occur, the medicine should be stopped. Avoid contact with eyes, mouth, corners of the nose and other mucous membranes. If the medicine gets into the eye, wash with plenty of water. Caution should be used when applying the medicine to the neck and other sensitive areas. The oxidizing action of the gel can discolor dyed hair and colored clothing. Do not apply to abraded or irritated skin. Avoid exposure to the sun and ultraviolet rays while applying benzoyl peroxide. \u003cu\u003ePediatric population\u003c\/u\u003e: No efficacy and safety data are available in children under 12 years of age. \u003cb\u003eBenzac 5% gel and Benzac 10% gel contain propylene glycol\u003c\/b\u003e Benzac 5% gel and Benzac 10% gel contain 4% propylene glycol, corresponding to 40 mg for each gram of gel.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of strong detergents, alcoholic products, anti-acne skin preparations and medicines used in the treatment of acne containing substances that can increase the effect \u003ci\u003epeeling,\u003c\/i\u003e irritants or that cause skin dryness, such as those based on tretinoin, resorcinol, salicylic acid and sulphides, medicated cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions resulting from clinical studies are all related to skin disorders. They are reversible if treatment is reduced in frequency or stopped. The frequency of adverse reactions is divided into the following categories: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). Adverse reactions are shown in the table below:\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: erythema, skin exfoliation (desquamation), burning sensation of the skin, dry skin.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin irritation (irritant contact dermatitis), pruritus, skin pain (pain, stinging).\u003c\/p\u003e\n\u003cp\u003eUncommon: allergic contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eCases of facial swelling and allergic reactions, including application site hypersensitivity and anaphylaxis, have been reported (frequency not known) from post-marketing pharmacovigilance data. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for cutaneous use only. Excessive application of the product does not lead to faster or better results but may cause irritation. If severe irritation develops, treatment should be discontinued and appropriate symptomatic therapy instituted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility, pregnancy: There are no safety concerns regarding the effects of benzoyl peroxide, applied to the skin, on reproductive function, fertility, teratogenicity, or peri- and post-natal development, in animals. Generalized clinical use for the skin treatment of acne vulgaris, for several decades, at concentrations of up to 10% w\/w of benzoyl peroxide has never been associated with such effects. In any case, the drug should be administered in cases of real need under the direct supervision of a doctor. Breastfeeding: It is not known whether benzoyl peroxide is excreted in animal or human milk. Because many drugs are excreted in breast milk, caution should be exercised when benzoyl peroxide gel is used by women who are breastfeeding. The preparation must not be applied to the breast to avoid accidental transfer to the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730204983623,"sku":"032143012","price":23.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-benzac-gel-10-40-g-gel-farmacia-dottor-tili-1213791388.jpg?v=1767139359"},{"product_id":"trans-ver-sal-13-5-mg-12-mm-20-cerotti-transdermici-garzette-e-limetta","title":"Trans - Ver - Sal 13.5 mg\/12 mm 20 transdermal patches + egrets and lime","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the treatment of common warts, calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003econtains.\u003c\/p\u003e\n\u003cp\u003eActive ingredient.\u003c\/p\u003e\n\u003cp\u003esalicylic acid mg - 6 mm: 3.75. 12mm: 13.5. 20mm: 36.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKaraya gum; propylene glycol; polyethylene glycol 300 quaternium 15\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. The product should not be used in case of diabetes or circulatory failure. Like all products with a high salicylic acid content, it should not be applied to the face, anogenital area and mucous membranes. The transdermal patch should not be applied to moles, seborrheic warts and warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a transdermal patch to the affected area in the evening and remove it the following morning. Repeat the application every 24 hours until the wart is eliminated. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially prolonged, of products for topical use can give rise to sensitization phenomena, in which case interrupt the treatment and institute a suitable therapy. Do not use for prolonged treatments, after a short period of treatment without appreciable results, consult your doctor. Avoid application on healthy skin surrounding the affected area. Keep out of reach of children. Avoid contact with eyes and mucous membranes. Do not use the product on irritated, infected or red skin. Do not ingest. In case of accidental ingestion, consult your doctor immediately. The product must not be used to prevent the formation of warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substance.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn some cases, intolerance (burning or irritation) may occur, however without consequences and which does not require modification of the treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBy following the instructions for use above, there is no possibility of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no limitations on use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Difa Cooper","offers":[{"title":"Default Title","offer_id":51730205049159,"sku":"034674022","price":21.38,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/difa-cooper-spa-trans-ver-sal-13-5-mg-12-mm-20-cerotti-transdermici-garzette-e-limetta-farmacia-dottor-tili-1213791386.jpg?v=1767139426"},{"product_id":"trans-ver-sal-3-75-mg-6-mm-20-cerotti-transdermici-garzette-e-limetta","title":"Trans - Ver - Sal 3.75 mg\/6 mm 20 transdermal patches + egrets and lime","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the treatment of common warts, calluses and calluses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003econtains.\u003c\/p\u003e\n\u003cp\u003eActive ingredient.\u003c\/p\u003e\n\u003cp\u003esalicylic acid mg - 6 mm: 3.75. 12mm: 13.5. 20mm: 36.3.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKaraya gum; propylene glycol; polyethylene glycol 300 quaternium 15\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. The product should not be used in case of diabetes or circulatory failure. Like all products with a high salicylic acid content, it should not be applied to the face, anogenital area and mucous membranes. The transdermal patch should not be applied to nevi, seborrheic warts and warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply a transdermal patch to the affected area in the evening and remove it the following morning. Repeat the application every 24 hours until the wart is eliminated. Do not exceed the recommended doses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially prolonged, of products for topical use can give rise to sensitization phenomena, in which case interrupt the treatment and institute a suitable therapy. Do not use for prolonged treatments, after a short period of treatment without appreciable results, consult your doctor. Avoid application on healthy skin surrounding the affected area. Keep out of reach of children. Avoid contact with eyes and mucous membranes. Do not use the product on irritated, infected or red skin. Do not ingest. In case of accidental ingestion, consult a doctor immediately. The product must not be used to prevent the formation of warts.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other keratolytics so as not to increase the caustic action of the active substance.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn some cases, intolerance (burning or irritation) may occur, however without consequences and which does not require modification of the treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBy following the instructions for use above, there is no possibility of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no limitations on use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNobody.\u003c\/p\u003e","brand":"Difa Cooper","offers":[{"title":"Default Title","offer_id":51730205114695,"sku":"034674010","price":21.38,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/difa-cooper-spa-trans-ver-sal-3-75-mg-6-mm-20-cerotti-transdermici-garzette-e-limetta-farmacia-dottor-tili-1213791384.jpg?v=1767139390"},{"product_id":"benzac-gel-5-40-g-gel","title":"Benzac Gel 5% 40g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSkin disinfection. It also has antiseptic activity against P. acnes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: Benzoyl Peroxide - BENZAC 10% gel: 10 g. BENZAC 5% gel: 5 g.\u003c\/p\u003e\n\u003cp\u003eExcipient with known effects: Propylene glycol (E1520) For the complete list of excipients, see paragraph 6.1 Rinse-off formulation 100 g of gel contain:\u003c\/p\u003e\n\u003cp\u003eActive ingredient: BENZAC 5% gel.\u003c\/p\u003e\n\u003cp\u003eBenzoyl Peroxide: 5 g.\u003c\/p\u003e\n\u003cp\u003eFor the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel and BENZAC 10% gel\u003c\/b\u003e Carbomer 940, Methacrylic copolymer, Glycerin, Disodium Edetate, Dioctyl sodium sulfosuccinate, Colloidal silica, Propylene glycol (E1520), Poloxamer 182, Demineralised water. \u003cb\u003eBENZAC 5% gel - rinse-off formulation\u003c\/b\u003e Acryl Copolymer, Carbomer 940, Sodium C14-C16 Olefin Sulphonate, Glycerol, Sodium Hydroxide, Demineralised Water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENZAC 5% gel\u003c\/b\u003e e \u003cb\u003eBENZAC 10% gel\u003c\/b\u003e: Apply Benzac locally on the skin, favoring its penetration with a light massage. Applications must be made once or twice a day, as needed, by spreading a small amount of Benzac with the fingertips on the affected parts, previously thoroughly cleaned with a mild detergent and dried carefully, massaging lightly until absorbed. People with sensitive skin should apply the gel once a day or once every two days before going to bed. \u003cb\u003eBENZAC 5% gel (rinse-off formulation)\u003c\/b\u003e: Apply the gel once or twice a day to the affected area. Moisten the application area. Place the required amount of BENZAC 5% gel on your fingertips and spread it on the various parts of the skin with a circular motion, as if washing. Skin contact time should be as short as possible (1 to 5 minutes) to minimize the risk of undesirable effects (see section 4.8). Rinse thoroughly with water and dry.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store Benzac above 25°C\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for external use only. The use, especially if prolonged, of products for skin use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Probably, at the first application you may feel a slight burning sensation and, within a few days, slight redness and peeling of the skin may occur. During the first weeks of treatment, a sudden increase in desquamation occurs in most patients. This is not dangerous and normally subsides within a day or two if treatment is temporarily stopped. Patients should be directed to use the drug less frequently, to temporarily discontinue or discontinue use, if severe irritation occurs. Benzoyl peroxide may cause swelling and blistering of the skin; if any of these symptoms occur, the medicine should be stopped. Avoid contact with eyes, mouth, corners of the nose and other mucous membranes. If the medicine gets into the eye, wash with plenty of water. Caution should be used when applying the medicine to the neck and other sensitive areas. The oxidizing action of the gel can discolor dyed hair and colored clothing. Do not apply to abraded or irritated skin. Avoid exposure to the sun and ultraviolet rays while applying benzoyl peroxide. \u003cu\u003ePediatric population\u003c\/u\u003e: No efficacy and safety data are available in children under 12 years of age. \u003cb\u003eBenzac 5% gel and Benzac 10% gel contain propylene glycol\u003c\/b\u003e Benzac 5% gel and Benzac 10% gel contain 4% propylene glycol, corresponding to 40 mg for each gram of gel.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of strong detergents, alcoholic products, anti-acne skin preparations and medicines used in the treatment of acne containing substances that can increase the effect \u003ci\u003epeeling,\u003c\/i\u003e irritants or that cause skin dryness, such as those based on tretinoin, resorcinol, salicylic acid and sulphides, medicated cosmetics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe adverse reactions resulting from clinical studies are all related to skin disorders. They are reversible if treatment is reduced in frequency or stopped. The frequency of adverse reactions is divided into the following categories: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). Adverse reactions are shown in the table below:\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eVery common: erythema, skin exfoliation (desquamation), skin burning sensation, skin dryness.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin irritation (irritant contact dermatitis), pruritus, skin pain (pain, stinging).\u003c\/p\u003e\n\u003cp\u003eUncommon: allergic contact dermatitis.\u003c\/p\u003e\n\u003cp\u003eCases of facial swelling and allergic reactions, including application site hypersensitivity and anaphylaxis, have been reported (frequency not known) from post-marketing pharmacovigilance data. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac is for cutaneous use only. Excessive application of the product does not lead to faster or better results but may cause irritation. If severe irritation develops, treatment should be discontinued and appropriate symptomatic therapy instituted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFertility, pregnancy: There are no safety concerns regarding the effects of benzoyl peroxide, applied to the skin, on reproductive function, fertility, teratogenicity, or peri- and post-natal development, in animals. Generalized clinical use for the skin treatment of acne vulgaris, for several decades, at concentrations of up to 10% w\/w of benzoyl peroxide has never been associated with such effects. In any case, the drug should be administered in cases of real need under the direct supervision of a doctor. Breastfeeding: It is not known whether benzoyl peroxide is excreted in animal or human milk. Because many drugs are excreted in breast milk, caution should be exercised when benzoyl peroxide gel is used by women who are breastfeeding. The preparation must not be applied to the breast to avoid accidental transfer to the infant.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenzac does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":51730205344071,"sku":"032143024","price":22.33,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/galderma-italia-spa-benzac-gel-5-40-g-gel-farmacia-dottor-tili-1213791382.jpg?v=1767139472"},{"product_id":"connettivina-plus-0-2-1-25-g-crema","title":"Connettivina Plus 0.2% + 1% 25 g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of mild wounds. Local treatment of 1st and 2nd degree burns\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCONNECTIVITY\u003c\/u\u003e \u003cu\u003ePLUS 2 mg\/g + 10 mg\/g cream\u003c\/u\u003e 1 g of cream contains 2 mg of hyaluronic acid sodium salt and 10 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes\u003c\/u\u003e Each 10x10 cm gauze is impregnated with 4 g of cream containing 2 mg of hyaluronic acid sodium salt and 40 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e Each 10x20 cm gauze is impregnated with 8 g of cream containing 4 mg of hyaluronic acid sodium salt and 80 mg of silver sulfadiazine. \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e Each 20x30 cm gauze is impregnated with 24 g of cream containing 12 mg of hyaluronic acid sodium salt and 240 mg of silver sulfadiazine. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eCONNETTIVIN PLUS 2 mg\/g + 10 mg\/g\u003c\/u\u003e \u003cu\u003ecream\u003c\/u\u003e \u003c\/b\u003e Polyethylene glycol 400 monostearate – oleic acid decyl ester – emulsifying wax – glycerol – sorbitol solution 70% – purified water \u003cu\u003eCONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e Polyethylene glycol 4000 – glycerol – purified water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances and other closely chemically related substances or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCONNETTIVINA PLUS 2 mg\/g + 10 mg\/g cream\u003c\/u\u003e: spread a uniform layer of cream 2–3 mm thick over the entire site of the lesion, once or twice a day. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes \u003cu\u003eCONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes\u003c\/u\u003e \u003cu\u003eCONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes\u003c\/u\u003e: Apply one or more medicated gauzes two or more times a day depending on the extent of the lesions. Before applying CONNETTIVINA PLUS, the affected areas must be cleaned preferably with sterile physiological solution (NaCl 0.9%) and disinfected using antiseptics preferably containing povidone iodine or chlorhexidine. If necessary, surgical cleaning must be carried out. In the treatment of burns, cleaning of the lesions is preferable to be carried out only with water or sterile physiological solution, avoiding disinfection with antiseptic agents before applying Connettivina PLUS cream or impregnated gauze. After cleansing the injured parts, spread a uniform layer of cream 2 or 3 mm thick or apply impregnated gauze. The application must continue as long as there is a possibility of infection and until complete healing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCONNETTIVINA PLUS must be used with caution in subjects who have shown previous allergies to sulphonamides and in the presence of hepatic or renal insufficiency.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with CONNETTIVINA PLUS, can be inactivated by the presence of silver ions. Do not use simultaneously with disinfectants containing quaternary ammonium salts as hyaluronic acid may precipitate in their presence.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAfter the application of CONNETTIVINA PLUS, local reactions (pain, burning, itching) may occur, even of an allergic nature. Since the systemic administration of sulphonamides can cause adverse reactions such as renal failure, toxic hepatitis, agranulocytosis, thrombocytopenia and leukopenia, it cannot be excluded that the local treatment of large parts of the body with CONNETTIVINA PLUS may give rise to side effects typical of sulphonamides administered systemically\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known cases of overdose.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the absence of data on the effects of the medicine on the fetus, CONNETTIVINA PLUS must not be used during pregnancy and breastfeeding unless the doctor considers that the therapeutic benefits outweigh the possible risks.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCONNETTIVINA PLUS does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Fidia","offers":[{"title":"Default Title","offer_id":51730206359879,"sku":"028440030","price":13.78,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/fidia-farmaceutici-spa-connettivina-plus-0-2-1-25-g-crema-farmacia-dottor-tili-1213791109.jpg?v=1767139991"},{"product_id":"sofargen-1-120-g-crema","title":"Sofargen 1% 120g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProphylaxis and local antibacterial treatment of infections in case of 2nd and 3rd degree burns; local antibacterial treatment of varicose ulcers and infected bedsores and in general of dermatological conditions that are infected or susceptible to superinfections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSOFARGEN 1% cream contains 1 g of micronized silver sulfadiazine. Excipients with known effects: stearyl alcohol, propylene glycol, methyl p-oxybenzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStearyl alcohol; isopropyl myristate; propylene glycol; polyethylene glycol monostearate; polyoxyethylene sorbitan monolaurate; methyl–p–oxybenzoate; distilled water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Since sulphonamides may increase the risk of neonatal jaundice, Sofargen should not be used in women at the end of pregnancy, in premature babies and in newborns in the first months of life.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn burns Sofargen should be applied as early as possible. After a quick cleansing of the injured parts, immediately spread a uniform layer of cream 2 or 3 mm thick on the burnt surfaces. The cream can be applied either directly to the lesions, possibly with the help of a sterile glove, or previously spread on sterile gauze. The application of Sofargen must continue without interruption, once or twice a day, as long as there is a possibility of infection and until complete healing, both in spontaneous and surgical repairs. At each renewal of the dressing, carefully cleanse the wounds with water or physiological solution by showering or sponging. Take care to promptly reapply the cream on surfaces from which it has been inadvertently removed. In other cases, varicose ulcers, bedsores, wounds and dermatological conditions susceptible to infection, cleanse the injured part where necessary and apply a layer of cream 2-3 mm thick, following the same criterion described for the treatment of burns. The lesion must always be kept completely covered by the medicine. If a knee-high type dressing is needed, unwrap 20-30 cm portions of a bandage of adequate length, spread a generous layer of cream, rewrap the impregnated part, unwrap another 20-30 cm and repeat the operation until the entire length of the bandage has been completely impregnated, then apply the required bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at temperatures below 30° C. The product must be used within 6 months of first opening the container.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen should be applied with caution in the presence of hepatic or renal insufficiency. The use of Sofargen may be risky in subjects with manifest glucose-6-phosphate dehydrogenase deficiency, as hemolytic phenomena may occur. Prolonged use of the product may give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and adopt suitable therapeutic measures. The same applies in case of superinfection by resistant microorganisms. In the treatment of burns of a large part of the body, serum concentrations of sulphonamide can reach therapeutic levels in adults. Therefore, in these patients it would be advisable to monitor these serum levels, renal function, the presence of any sulphonamide crystals in the urine and liver function, interrupting therapy if liver and\/or renal function is compromised. Furthermore, given that propylene glycol, present as an excipient in the composition, can cause hyperosmolality when the product is applied to large burn areas, serum osmolality must be periodically checked and, if necessary, the treatment must be interrupted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with Sofargen, can be inactivated by the presence of silver ions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome cases of transient leukopenia (0.4%), rare local disorders (pain and burning) and rare local allergic reactions (0.3%) have been reported. The classic side effects of systemically administered sulphonamides cannot be excluded when treating large parts of the body. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo symptoms of overdose have been highlighted in the literature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there is no exhaustive experimental data on the possible effects of the drug on the fetus, Sofargen should not be used during pregnancy and breastfeeding unless, in the opinion of the doctor, its use is indispensable and essential for the pregnant woman (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211373383,"sku":"025561073","price":24.83,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-sofargen-1-120-g-crema-farmacia-dottor-tili-1213791028.jpg?v=1767164747"},{"product_id":"sofargen-1-30-g-crema","title":"Sofargen 1% 30g cream","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProphylaxis and local antibacterial treatment of infections in case of 2nd and 3rd degree burns; local antibacterial treatment of varicose ulcers and infected bedsores and in general of dermatological conditions that are infected or susceptible to superinfections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSOFARGEN 1% cream contains 1 g of micronized silver sulfadiazine. Excipients with known effects: stearyl alcohol, propylene glycol, methyl p-oxybenzoate. For the full list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStearyl alcohol; isopropyl myristate; propylene glycol; polyethylene glycol monostearate; polyoxyethylene sorbitan monolaurate; methyl–p–oxybenzoate; distilled water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients. Since sulphonamides may increase the risk of neonatal jaundice, Sofargen should not be used in women at the end of pregnancy, in premature babies and in newborns in the first months of life.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn burns Sofargen should be applied as early as possible. After a quick cleansing of the injured parts, immediately spread a uniform layer of cream 2 or 3 mm thick on the burnt surfaces. The cream can be applied either directly to the lesions, possibly with the help of a sterile glove, or previously spread on sterile gauze. The application of Sofargen must continue without interruption, once or twice a day, as long as there is a possibility of infection and until complete healing, both in spontaneous and surgical repairs. At each renewal of the dressing, carefully cleanse the wounds with water or physiological solution by showering or sponging. Take care to promptly reapply the cream on surfaces from which it has been inadvertently removed. In other cases, varicose ulcers, bedsores, wounds and dermatological conditions susceptible to infection, cleanse the injured part where necessary and apply a layer of cream 2-3 mm thick, following the same criterion described for the treatment of burns. The lesion must always be kept completely covered by the medicine. If a knee-high type dressing is needed, unwrap 20-30 cm portions of a bandage of adequate length, spread a generous layer of cream, rewrap the impregnated part, unwrap another 20-30 cm and repeat the operation until the entire length of the bandage has been completely impregnated, then apply the required bandage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore at temperatures below 30° C. The product must be used within 6 months of first opening the container.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen should be applied with caution in the presence of hepatic or renal insufficiency. The use of Sofargen may be risky in subjects with manifest glucose-6-phosphate dehydrogenase deficiency, as hemolytic phenomena may occur. Prolonged use of the product may give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and adopt suitable therapeutic measures. The same applies in case of superinfection by resistant microorganisms. In the treatment of burns of a large part of the body, serum concentrations of sulphonamide can reach therapeutic levels in adults. Therefore, in these patients it would be advisable to monitor these serum levels, renal function, the presence of any sulphonamide crystals in the urine and liver function, interrupting therapy if liver and\/or renal function is compromised. Furthermore, given that propylene glycol, present as an excipient in the composition, can cause hyperosmolality when the product is applied to large burn areas, serum osmolality must be periodically checked and, if necessary, the treatment must be interrupted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal proteolytic enzymes, applied simultaneously with Sofargen, can be inactivated by the presence of silver ions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSome cases of transient leukopenia (0.4%), rare local disorders (pain and burning) and rare local allergic reactions (0.3%) have been reported. The classic side effects of systemically administered sulphonamides cannot be excluded when treating large parts of the body. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo symptoms of overdose have been highlighted in the literature.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince there is no exhaustive experimental data on the possible effects of the drug on the fetus, Sofargen should not be used during pregnancy and breastfeeding unless, in the opinion of the doctor, its use is indispensable and essential for the pregnant woman (see 4.3).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSofargen does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730211701063,"sku":"025561010","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-sofargen-1-30-g-crema-farmacia-dottor-tili-1213791018.jpg?v=1767164908"},{"product_id":"acido-salicilico-marco-viti-10-30-g-unguento","title":"Salicylic acid Marco Viti 10% 30 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e– Treatment of psoriasis, acne vulgaris, seborrhea in adults and children; – Removal of warts and calluses in adults and children; – Local treatment of some forms of eczema and ichthyosis in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid Marco Viti 2% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 2 g. Salicylic acid Marco Viti 5% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 5 g. Salicylic acid Marco Viti 10% ointment 100 g of ointment contain \u003ci\u003eActive ingredient\u003c\/i\u003e: salicylic acid 10 g. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhite Vaseline.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e– hypersensitivity to the active ingredient, to salicylates or to any of the excipients (patients hypersensitive to salicylates, such as acetylsalicylic acid, propylsalicylate, bromosacylic acid, zinc salicylate, may also be hypersensitive to salicylic acid); – children under the age of 2; – diabetes (see section 4.8); – peripheral vascular disease.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply locally the minimum quantity of ointment in relation to the area to be treated with a light massage. Begin treatment by applying the medicine only to a small portion of the skin or only once a day, so as not to irritate the skin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in a tightly closed container, protected from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine must not be swallowed. Salicylic acid is irritating and could cause dermatitis (see section 4.8); When treating calluses and warts, it is necessary to protect the surrounding intact skin to minimize the absorption of the active ingredient. Salicylic acid must not be used for long periods of time, at high concentrations, on large areas of the body, or on damaged or inflamed skin, as excessive absorption of the active ingredient can cause systemic salicylate poisoning (see section 4.9) mainly in children, which can be fatal. Avoid contact with mouth, eyes, genitals and other mucous membranes. Use with caution in children as experience on the use of salicylic acid in this population is limited. It is possible to observe an improvement in the treated skin after 6 weeks of therapy or after 12 weeks in the case of removal of a wart.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid may interact with the following medicines: – Coumarin anticoagulants (acenocoumarol, dicoumarol, phenprocumon and warfarin) and 1,3-idandione derivatives (anisindione, phenidione), as salicylic acid can inhibit platelet aggregation and displace them from their binding site with plasma proteins, thus causing an increased risk of bleeding. – Inhibitors of coagulation-activated factor – Glyburide, since, due to an unknown mechanism, excessive hypoglycemia could occur. – Probenecid, as salicylic acid can cause the reversal of the uricosuric effects of this drug. – Acetazolamide, as you may experience an increase in side effects of salicylate. – Chickenpox vaccine, as salicylic acid may cause an increased risk of developing Reye's syndrome. Furthermore, salicylic acid should not be used at the same time as tamarind (tropical tree belonging to the \u003ci\u003eFabaceae\u003c\/i\u003e) and Salvia miltiorrhiza or Tan–Shen (plant of the \u003ci\u003eLabiateae\u003c\/i\u003e), as there could be a rapid increase in plasma levels of salicylate with consequent increase in toxicity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of salicylic acid, organized according to the MedDRA systemic classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003eMetabolism and nutrition disorders\u003c\/i\u003e Hypoglycemia. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Irritations, dermatitis, burning, itching, erythema, peeling of the skin, scars on the face.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose with topically applied salicylic acid have been reported. However, in case of excessive absorption of the active ingredient (e.g. prolonged application on large areas of the body or on damaged and inflamed skin) a state of salicylism could occur. The symptoms of salicylism are: nausea, vomiting, tinnitus (or tinnitus) and dizziness. Rarely, the following may occur: gastric ulcer, asthma, hepatotoxicity, renal failure and pancreatic toxicity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no adequate data regarding the use of salicylic acid in pregnant and breastfeeding women. Therefore, salicylic acid solutions and ointments should not be used during pregnancy and breastfeeding unless absolutely necessary. Studies conducted on animals have shown reproductive toxicity (see section 5.3). While the potential risk for humans is unknown. However, it should be considered that despite being used topically, salicylic acid is absorbed systemically, easily crosses the placenta, finding itself in higher concentrations in fetal plasma and is excreted in breast milk (see section 5.2).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylic acid does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51730211766599,"sku":"030354031","price":5.12,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-acido-salicilico-marco-viti-10-30-g-unguento-farmacia-dottor-tili-1213791017.jpg?v=1767164889"},{"product_id":"ictammolo-marco-viti-10-50-g-unguento","title":"Ictammol Marco Viti 10% 50 g ointment","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eInflammations and small skin infections. Furunculosis (pimples), abscesses and superficial skin ulcerations. Inflammation of the sweat glands (hidradenitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of ointment contain Active ingredient: ammonium sulfoicthiolate 10 g. \u003ci\u003eFor the full list of excipients, see section 6.1.\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhite Vaseline.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eApply the ointment, in the quantity necessary in relation to the part to be treated, 2-3 times a day, covering with gauze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore the container tightly closed in the original packaging protected from light.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not apply near the eyes and on the mucous membranes. Avoid exposure to the sun and UVA rays after application. The use, especially if prolonged, of medicines for local use can give rise to irritation or sensitization phenomena. If this occurs, discontinue treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo specific interaction studies have been performed.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBelow are the side effects of Ictammol, organized according to the MedDRA system organ classification. There is insufficient data to establish the frequency of the individual effects listed. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Dermatitis, burning, skin irritation, hypersensitivity reactions\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf used in excessive quantities it can be irritating to the skin and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the absence of specific studies, the medicine should be used during pregnancy and breastfeeding only if necessary and under direct medical supervision.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicine does not alter the ability to drive or use machines.\u003c\/p\u003e","brand":"Marco Viti","offers":[{"title":"Default Title","offer_id":51730213536071,"sku":"030338026","price":5.39,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/marco-viti-farmaceutici-spa-ictammolo-marco-viti-10-50-g-unguento-farmacia-dottor-tili-1213790999.jpg?v=1767156009"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/farmaci-per-infezioni-e-lesioni-della-pelle.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}